Jubilant Ingrevia Ltd. (IN:JUBLINGREA)
:JUBLINGREA
Top Page
Jubilant Ingrevia Ltd.
(JUBLINGREA)
Select Model
Select Model
Rating:61Neutral
Price Target:
₹625.00
▼(-13.91% Downside)
Action:ReiteratedDate:02/10/26
The score is primarily supported by solid underlying financial performance (profitability, stable margins, and generally improving cash generation). Offsetting this are weaker technical signals (negative MACD and price below key longer-term moving averages) and a high P/E with a low dividend yield, which together limit upside confidence.
Positive Factors
Integrated manufacturing platform
Vertical integration across chemical synthesis and fermentation provides durable cost and supply advantages. It supports cross-segment scale, reduces reliance on third-party suppliers, and enables win of long-term B2B contracts across pharma, nutrition and agro markets, sustaining revenue visibility.
Negative Factors
Revenue volatility
A material revenue dip followed by rebound signals demand sensitivity across end markets. Persistent volatility complicates capacity utilization, margins forecasting and contract negotiations, and can pressure working capital and investment decisions if recurrence occurs over future quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Integrated manufacturing platform
Vertical integration across chemical synthesis and fermentation provides durable cost and supply advantages. It supports cross-segment scale, reduces reliance on third-party suppliers, and enables win of long-term B2B contracts across pharma, nutrition and agro markets, sustaining revenue visibility.
Read all positive factors
Jubilant Ingrevia Ltd. (JUBLINGREA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹103.31B
Dividend Yield0.74%
Average Volume (3M)13.09K
Price to Earnings (P/E)59.2
Beta (1Y)1.01
Revenue Growth3.80%
EPS Growth64.94%
CountryIN
Employees2,283
SectorBasic Materials
Sector Strength58
IndustryBiotechnology
Share Statistics
EPS (TTM)3.60
Shares Outstanding159,281,140
10 Day Avg. Volume10,350
30 Day Avg. Volume13,091
Financial Highlights & Ratios
PEG Ratio1.10
Price to Book (P/B)3.53
Price to Sales (P/S)2.51
P/FCF Ratio72.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)23.57
Revenue Forecast (FY)₹52.40B
Jubilant Ingrevia Ltd. Business Overview & Revenue Model
Company Description
Jubilant Ingrevia Limited provides life science products and solutions in India and internationally. It operates in three segments: Specialty Chemicals, Nutrition & Health Solutions, and Life Science Chemicals. The Specialty Chemicals segment offe...
How the Company Makes Money
Jubilant Ingrevia primarily makes money by manufacturing and selling ingredients and intermediates to business customers (B2B) across multiple end markets. Its revenue model is product-sales driven: (1) Specialty chemicals and chemical intermediat...
Jubilant Ingrevia Ltd. Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
68
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 42.34B | 41.24B | 41.00B | 47.40B | 49.14B | 6.79B |
| Gross Profit | 16.71B | 19.00B | 18.50B | 20.44B | 19.56B | 2.78B |
| EBITDA | 6.02B | 5.56B | 4.56B | 5.79B | 8.59B | 1.06B |
| Net Income | 2.88B | 2.51B | 1.83B | 3.07B | 4.77B | 543.59M |
Balance Sheet | ||||||
| Total Assets | 52.57B | 50.32B | 47.32B | 42.59B | 37.97B | 33.79B |
| Cash, Cash Equivalents and Short-Term Investments | 469.10M | 1.15B | 828.36M | 1.08B | 454.69M | 1.17B |
| Total Debt | 8.06B | 7.64B | 7.40B | 4.07B | 2.38B | 5.56B |
| Total Liabilities | 22.16B | 21.05B | 19.94B | 15.93B | 13.64B | 14.56B |
| Stockholders Equity | 30.41B | 29.27B | 27.37B | 26.66B | 24.33B | 19.23B |
Cash Flow | ||||||
| Free Cash Flow | -365.90M | 1.42B | -1.38B | -189.30M | 2.23B | 847.36M |
| Operating Cash Flow | 970.80M | 5.08B | 4.30B | 4.62B | 4.53B | 1.12B |
| Investing Cash Flow | -962.50M | -3.93B | -5.70B | -4.72B | -718.56M | -436.55M |
| Financing Cash Flow | -495.40M | -1.29B | 1.44B | 416.00M | -4.18B | -723.65M |
Jubilant Ingrevia Ltd. Technical Analysis
Positive
726.00
Price Trends
601.31
Positive
648.63
Negative
684.18
Negative
Market Momentum
8.25
Negative
64.89
Neutral
77.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JUBLINGREA, the sentiment is Positive. The current price of 726 is above the 20-day moving average (MA) of 582.36, above the 50-day MA of 601.31, and above the 200-day MA of 684.18, indicating a neutral trend. The MACD of 8.25 indicates Negative momentum. The RSI at 64.89 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JUBLINGREA.
Jubilant Ingrevia Ltd. Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | ₹146.45B | 76.50 | ― | 0.06% | 69.32% | 113.55% | |
64 Neutral | ₹113.19B | 35.11 | ― | 0.15% | 24.25% | 96.45% | |
62 Neutral | ₹69.88B | 48.28 | ― | 0.62% | 3.95% | 8.28% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
61 Neutral | ₹103.31B | 59.25 | ― | 0.74% | 3.80% | 64.94% | |
49 Neutral | ₹64.05B | -16.12 | ― | 0.46% | 159.81% | -63.02% |
* Basic Materials Sector Average
IN:JUBLINGREA
Jubilant Ingrevia Ltd.
648.60
19.96
3.18%
IN:ALKYLAMINE
Alkyl Amines Chemicals Limited
1,397.20
-366.69
-20.79%
IN:ANURAS
Anupam Rasayan India Ltd.
1,286.35
537.29
71.73%
IN:PRIVISCL
Privi Speciality Chemicals Limited
2,897.65
1,035.44
55.60%
IN:SUDARSCHEM
Sudarshan Chemical Industries Limited
814.80
-206.92
-20.25%
Jubilant Ingrevia Ltd. Corporate Events
Jubilant Ingrevia to Acquire Remidex Pharma, Expands in Human Nutrition Premixes
Mar 13, 2026
Jubilant Ingrevia Limited has signed a share purchase agreement to acquire 100% of Remidex Pharma Private Limited, a Bengaluru-based manufacturer of micronutrient premixes, nutraceuticals, and a contract manufacturer for major Indian and multinati...
Jubilant Ingrevia Launches Electronic Postal Ballot for Shareholder Approval
Mar 5, 2026
Jubilant Ingrevia Ltd. has initiated a postal ballot process to seek shareholder approval on a resolution, circulating the notice and explanatory statement electronically in line with provisions of the Companies Act and SEBI listing regulations. T...
Jubilant Ingrevia Posts Stable Q3 FY26 Margins on Volume Growth, Declares Interim Dividend
Feb 5, 2026
Jubilant Ingrevia’s board has approved the financial results for the quarter ended 31 December 2025, reporting stable overall performance despite soft pricing across all three business segments. For Q3 FY26, total revenue stood at ₹1,0...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.